Economics, Pharmaceutical
"Economics, Pharmaceutical" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Economic aspects of the fields of pharmacy and pharmacology as they apply to the development and study of medical economics in rational drug therapy and the impact of pharmaceuticals on the cost of medical care. Pharmaceutical economics also includes the economic considerations of the pharmaceutical care delivery system and in drug prescribing, particularly of cost-benefit values. (From J Res Pharm Econ 1989;1(1); PharmacoEcon 1992;1(1))
| Descriptor ID |
D017850
|
| MeSH Number(s) |
N03.219.390
|
| Concept/Terms |
Pharmacy Economics- Pharmacy Economics
- Economic, Pharmacy
- Economics, Pharmacy
- Pharmacy Economic
|
Below are MeSH descriptors whose meaning is more general than "Economics, Pharmaceutical".
Below are MeSH descriptors whose meaning is more specific than "Economics, Pharmaceutical".
This graph shows the total number of publications written about "Economics, Pharmaceutical" by people in this website by year, and whether "Economics, Pharmaceutical" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2004 | 0 | 1 | 1 |
| 2006 | 0 | 1 | 1 |
| 2016 | 0 | 1 | 1 |
| 2017 | 7 | 4 | 11 |
| 2018 | 2 | 6 | 8 |
| 2019 | 1 | 0 | 1 |
| 2021 | 1 | 1 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Economics, Pharmaceutical" by people in Profiles.
-
International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Annual Meeting (May 17-20, 2021 - Virtual Meeting). Drugs Today (Barc). 2021 Aug; 57(8):519-525.
-
National trends in prescription drug expenditures and projections for 2021. Am J Health Syst Pharm. 2021 07 09; 78(14):1294-1308.
-
Patient-blood management for COVID19 convalescent plasma therapy: relevance of affinity and donor-recipient differences in concentration of neutralizing antibodies. Clin Microbiol Infect. 2021 Jul; 27(7):987-992.
-
Coronavirus Disease 2019: Considerations for Health Technology Assessment From the National Centre for Pharmacoeconomics Review Group. Value Health. 2020 11; 23(11):1423-1426.
-
Biosimilars for the Management of Inflammatory Bowel Diseases: Economic Considerations. Curr Med Chem. 2019; 26(2):259-269.
-
Cost-Effectiveness Analysis of Patiromer and Spironolactone Therapy in Heart Failure Patients with Hyperkalemia. Pharmacoeconomics. 2018 12; 36(12):1463-1473.
-
Cost Effectiveness of Quadrivalent Influenza Vaccines Compared with Trivalent Influenza Vaccines in Young Children and Older Adults in Korea. Pharmacoeconomics. 2018 12; 36(12):1475-1490.
-
Patterns of practice and pharmacoeconomic analysis of the management of patients with metastatic renal cell carcinoma (mRCC) in Greece--the CRISIS study. A retrospective analysis by the Hellenic Genitourinary Cancer Group (HGUCG). Expert Rev Pharmacoecon Outcomes Res. 2019 Aug; 19(4):491-501.
-
Untargeted Antifungal Treatment in Nonneutropenic Critically Ill Patients: Should Further Studies Be Performed Based on Trial Sequential Analysis Results? Antimicrob Agents Chemother. 2018 07; 62(7).
-
Evaluating quantity and quality of literature focusing on health economics and pharmacoeconomics in Gulf Cooperation Council countries. Expert Rev Pharmacoecon Outcomes Res. 2018 Aug; 18(4):403-414.